We observed complete elimination of tumor-specific mutations in cfDNA at the postoperative timepoint for four patients with major tumor responses (TRG 1 and TRG 2), including in patient CGST32, who exhibited baseline mutant allele fraction concentrations of 0.65% and 0.24% for BRAF G469A and KRAS G13R, respectively (Fig. 4a). This evidence concerns the gene BRAF and neoplasm.